Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Department of Gynecology, Yiyang Central Hospital, Yiyang, Hunan, China.
J Clin Pathol. 2021 Dec;74(12):787-795. doi: 10.1136/jclinpath-2020-206889. Epub 2020 Oct 15.
To explore the expression of secretagogin (SCGN) in neuroendocrine carcinoma of the uterine cervix and analyse its relationship with clinicopathological characteristics and prognosis.
From January 2010 to December 2017, 44 patients with cervical neuroendocrine carcinoma undergoing surgery were included in the study group, and 55 patients with cervical non-neuroendocrine carcinoma (including 30 cases of cervical squamous cell carcinoma and 25 cases of cervical adenocarcinoma) undergoing surgery were included in the control group. Immunohistochemical staining of SCGN was performed in both groups and compared with three common neuroendocrine markers, chromogranin A, synaptophysin (Syn) and CD56 in the study group. Detailed clinicopathological data of the two groups were analysed, and the patient survival in the study group was followed up.
The positive expression of SCGN in cervical neuroendocrine carcinoma, cervical adenocarcinoma and squamous cell carcinoma was 65.9% (29/44), 8% (2/25) and 0%, respectively. The positive expression of SCGN in cervical neuroendocrine carcinoma was significantly higher than that in cervical adenocarcinoma and squamous cell carcinoma (χ=44.5, p<0.001). There were no statistical differences among the positive expression of SCGN and three common neuroendocrine markers (p>0.05 for all). The intensity of SCGN staining in patients with cervical neuroendocrine carcinoma with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (p=0.020). However, there was no significant association between SCGN expression and survival among patients with cervical neuroendocrine carcinoma (p=0.633).
SCGN is a new neuroendocrine marker for cervical neuroendocrine carcinoma, whose expression correlates with lymph node metastasis.
探讨分泌颗粒素（SCGN）在宫颈神经内分泌癌中的表达，并分析其与临床病理特征和预后的关系。
纳入 2010 年 1 月至 2017 年 12 月间行手术治疗的 44 例宫颈神经内分泌癌患者为研究组，纳入同期行手术治疗的 55 例非宫颈神经内分泌癌患者（包括 30 例宫颈鳞癌和 25 例宫颈腺癌）为对照组。对两组患者均行 SCGN 免疫组织化学染色，并与研究组中三种常见的神经内分泌标志物（嗜铬粒蛋白 A、突触素（Syn）和 CD56）进行比较。分析两组的详细临床病理资料，并对研究组患者进行生存随访。
SCGN 在宫颈神经内分泌癌、宫颈腺癌和鳞癌中的阳性表达率分别为 65.9%（29/44）、8%（2/25）和 0%，宫颈神经内分泌癌中 SCGN 的阳性表达率显著高于宫颈腺癌和鳞癌（χ²=44.5，p<0.001）。SCGN 的阳性表达与三种常见的神经内分泌标志物之间均无统计学差异（p>0.05 均）。有淋巴结转移的宫颈神经内分泌癌患者的 SCGN 染色强度明显高于无淋巴结转移的患者（p=0.020）。然而，SCGN 表达与宫颈神经内分泌癌患者的生存之间无显著相关性（p=0.633）。
SCGN 是宫颈神经内分泌癌的一种新的神经内分泌标志物，其表达与淋巴结转移相关。
